Le Lézard
Classified in: Health, Science and technology, Business
Subjects: TNM, SVY, MAT

PURA CBD Gummies Backed by U.S. Patent and Research


DALLAS, April 23, 2020 /PRNewswire/ -- Puration, Inc. (USOTC: PURA) today emphasized that the company's recent acquisition of the Hemp4mula confections business includes access to a U.S. Patented cannabis extraction process and the university medical research behind the patented extraction process.  Puration has the only license of the NCM Biotech Patented Extraction process. NCM Biotech is focused on medical research and Puration has access to that research. "We by no means plan to get into the pharmaceutical business," explained Brian Shibley, CEO of Puration. "But we do look forward to having the ability to back the benefits of our Puration CBD Gummies and Gum with research."

See a recent research report on CBD extracts derived from NCM Biotech's patented extraction process: Journal of Cannabis Research

Puration is working now to rebrand Hemp4mula, and research backed benefits are intended to be an instrumental component of the new branding.

For more information on Puration, visit http://www.purationinc.com

Disclaimer/Safe Harbor: 

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. 

Contact:

Puration, Inc.
Brian Shibley,
[email protected]
+1-(800) 861-1350

SOURCE Puration, Inc.


These press releases may also interest you

at 12:24
West Physics Announces Acquisition of Tricord, Inc.
West Physics Consulting, LLC ("West Physics"), the leading national provider of integrated medical and health physics services, announced today that it has completed the purchase of the medical physics service division of Tricord, Inc. ("Tricord"), a...

at 12:16
Amae Health, Innovative Treatment Provider for Severe Mental Illness, Announces Closing of Oversubscribed $15 Million Series A Funding Round
Amae Health, a trailblazer in delivering patient-centered care for people with severe mental illness, announced today the successful closing of its oversubscribed $15 million Series A funding round. The round was led by Quiet Capital and included...

at 12:08
Roivios Secures FDA Breakthrough Device Designation for JuxtaFlow® RAD, Showcases Pioneering Data at Society of Cardiovascular Anesthesiologists Annual Meeting
Roivios, a pioneering clinical-stage medical device company dedicated to transforming kidney health, is thrilled to announce it has been awarded the prestigious Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for its...

at 12:06
Burrell College of Osteopathic Medicine Achieves Highest Accreditation Status from AOA Commission on Osteopathic College Accreditation
Burrell College of Osteopathic Medicine (BCOM) attained the highest level of accreditation from the American Osteopathic Association (AOA) Commission on Osteopathic College Accreditation (COCA). Burrell has been awarded the prestigious accreditation...

at 12:05
Radiance Biopharma to Present at LSX World Congress 2024
Radiance Biopharma ("Radiance" or the "Company"), a biopharmaceutical company specializing in the development of novel Antibody Drug Conjugates (ADCs) and Bispecific ADCs (BsADCs) treatments for cancers, today announced that...

at 12:01
Report from Orexo AB's annual general meeting, 26 April 2024
Election of the board of directors and auditor The annual general meeting in Orexo AB (publ) on 26 April 2024 resolved, in accordance with the nomination committee's proposal, that the number of board members shall be five with no deputy board...

More news about Health...


News published on and distributed by: